Chiesi Hellas
Chiesi Hellas is a pharmaceutical company committed to research, innovation, and providing healthcare solutions. It is part of the international Chiesi Group, which focuses on developing and distributing medicines for rare and complex diseases, respiratory, neonatal, and other therapeutic areas. The company emphasizes sustainability, social responsibility, and patient-centered care. It operates within a global network of subsidiaries across numerous countries, including Germany, Austria, Belgium, Brazil, Bulgaria, China, Slovenia, Spain, USA, France, Greece, Netherlands, Hungary, Italy, Mexico, Pakistan, Poland, Russia, UK, Slovakia, Czech Republic, Romania, Sweden, and Turkey.
Industries
Nr. of Employees
medium (51-250)
Chiesi Hellas
Pl. Geroulanou & Renu Poggi 1, 174 55 Alimos, Athens
Products
CE-marked mobile app for pulmonary rehabilitation (clinical evaluation ongoing)
A smartphone/tablet software application delivering personalised pulmonary rehabilitation and educational modules for chronic obstructive pulmonary disease; evaluated in pilot studies and ongoing randomized clinical trials in Europe. CE marked as a medical device in the relevant jurisdiction.
Pegunigalsidase alfa (development-stage enzyme-replacement therapy)
Development-stage enzyme-replacement therapy candidate for treatment of Fabry disease (investigational).
Velmanase alfa (enzyme-replacement therapy for alpha-mannosidosis)
Enzyme-replacement therapy indicated for non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.
Cysteamine bitartrate (therapy for nephropathic cystinosis)
Oral cysteamine therapy indicated to reduce intracellular cystine accumulation in patients with nephropathic cystinosis and delay renal deterioration when started early.
Deferiprone (oral iron chelation therapy)
Oral small-molecule iron chelator used to treat iron overload in patients with transfusion-dependent thalassemia.
Idebenone (therapy for hereditary optic neuropathy)
Small-molecule therapy indicated for treatment of vision disorders associated with hereditary optic neuropathy (Leber's hereditary optic neuropathy).
CE-marked mobile app for pulmonary rehabilitation (clinical evaluation ongoing)
A smartphone/tablet software application delivering personalised pulmonary rehabilitation and educational modules for chronic obstructive pulmonary disease; evaluated in pilot studies and ongoing randomized clinical trials in Europe. CE marked as a medical device in the relevant jurisdiction.
Pegunigalsidase alfa (development-stage enzyme-replacement therapy)
Development-stage enzyme-replacement therapy candidate for treatment of Fabry disease (investigational).
Velmanase alfa (enzyme-replacement therapy for alpha-mannosidosis)
Enzyme-replacement therapy indicated for non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.
Cysteamine bitartrate (therapy for nephropathic cystinosis)
Oral cysteamine therapy indicated to reduce intracellular cystine accumulation in patients with nephropathic cystinosis and delay renal deterioration when started early.
Deferiprone (oral iron chelation therapy)
Oral small-molecule iron chelator used to treat iron overload in patients with transfusion-dependent thalassemia.
Idebenone (therapy for hereditary optic neuropathy)
Small-molecule therapy indicated for treatment of vision disorders associated with hereditary optic neuropathy (Leber's hereditary optic neuropathy).
Services
Sponsorship and organisation of scientific talks, satellite symposia, clinician educational activities at medical congresses and support for clinician-facing training.
Post-market safety monitoring and adverse event reporting processes to support regulatory compliance for marketed medicinal products.
Management of marketing authorisations including transfers between marketing-authorisation holders and related regulatory communications.
Sponsorship of research fellowships and grants to support clinical and translational research in pulmonology and related fields.
Support and sponsorship of public health events offering basic respiratory screening (eg, spirometry) delivered with local clinicians to raise awareness and facilitate early detection.
Commercial partnership model to distribute a CE-marked mobile pulmonary rehabilitation application in regional markets, enabling remote delivery of personalised rehabilitation programs with clinician support.
Sponsorship and organisation of scientific talks, satellite symposia, clinician educational activities at medical congresses and support for clinician-facing training.
Post-market safety monitoring and adverse event reporting processes to support regulatory compliance for marketed medicinal products.
Management of marketing authorisations including transfers between marketing-authorisation holders and related regulatory communications.
Sponsorship of research fellowships and grants to support clinical and translational research in pulmonology and related fields.
Support and sponsorship of public health events offering basic respiratory screening (eg, spirometry) delivered with local clinicians to raise awareness and facilitate early detection.
Commercial partnership model to distribute a CE-marked mobile pulmonary rehabilitation application in regional markets, enabling remote delivery of personalised rehabilitation programs with clinician support.
Expertise Areas
- Neonatology
- Respiratory drug development
- Inhalation drug delivery and device engineering
- Digital therapeutics and mobile health
Key Technologies
- Inhalation particle engineering for pulmonary deposition
- Pressurized metered-dose and dry powder inhaler platforms
- Parenteral, oral and intratracheal formulation technologies
- Pulmonary surfactant preparations for intratracheal administration
News & Updates
25th Panhellenic Congress on Thoracic Diseases
Participation in the congress with presentations on caffeine's effects on apnea and retinopathy of prematurity, and on its impact on bronchopulmonary dysplasia and neurological outcomes.
80 Years of Chiesi Group's Contribution to Health and Research
Celebration of the company's long history with events and exhibitions highlighting its commitment to health and innovation.
3rd Panhellenic Sales Conference
Conference focusing on sales strategies and digital channels, with participation from company representatives.
32nd Panhellenic Cardiology Convention
Participation in the cardiology conference with a focus on cardiovascular health.
Chiesi Group Achieves B Corp Certification
Highlighting the company's commitment to social and environmental responsibility.
Innovations in Respiratory Medicine
Recent advancements and research in respiratory treatments.
25th Panhellenic Congress on Thoracic Diseases
Participation in the congress with presentations on caffeine's effects on apnea and retinopathy of prematurity, and on its impact on bronchopulmonary dysplasia and neurological outcomes.
80 Years of Chiesi Group's Contribution to Health and Research
Celebration of the company's long history with events and exhibitions highlighting its commitment to health and innovation.
3rd Panhellenic Sales Conference
Conference focusing on sales strategies and digital channels, with participation from company representatives.
32nd Panhellenic Cardiology Convention
Participation in the cardiology conference with a focus on cardiovascular health.
Chiesi Group Achieves B Corp Certification
Highlighting the company's commitment to social and environmental responsibility.
Innovations in Respiratory Medicine
Recent advancements and research in respiratory treatments.